Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27
Details of the Proffered Paper Oral PresentationTitle: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)Presenter: Sumanta Pal, M.D., FASCO, Professor and
Xencor's new cancer medicine called XmAb819 showed results from early testing that are important enough for doctors to present at a big medical conference. When a company shares study results publicly like this, it helps investors understand if the medicine might work, so watch for what doctors say about whether patients improved.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.